A high-throughput clinical assay for testing drug facilitation of exposure therapy

Depression and Anxiety

Volumn 30, Issue 7, 2013, Pages 631-637

  Rodebaugh, Thomas L ^a   Levinson, Cheri A ^a   Lenze, Eric J ^a  

^a WASHINGTON UNIVERSITY   (United States)

Author keywords

anxiety disorders; cognitive behavioral therapy; D cycloserine; exposure therapy; social anxiety; social anxiety disorder; social phobia

Indexed keywords

CYCLOSERINE;

ADULT; ANXIETY; ARTICLE; CLINICAL ARTICLE; DISTRESS SYNDROME; DRUG DEPENDENCE; DRUG EXPOSURE; FEAR; FEMALE; HIGH THROUGHPUT SCREENING; HUMAN; MALE; PRIORITY JOURNAL; SOCIAL PHOBIA; SPEECH; VIDEOTAPE;

ANXIETY DISORDERS; COGNITIVE BEHAVIORAL THERAPY; D-CYCLOSERINE; EXPOSURE THERAPY; SOCIAL ANXIETY; SOCIAL ANXIETY DISORDER; SOCIAL PHOBIA;

ADULT; ANALYSIS OF VARIANCE; COMBINED MODALITY THERAPY; CYCLOSERINE; FEAR; FEMALE; HUMANS; IMPLOSIVE THERAPY; MALE; MIDDLE AGED; PHOBIC DISORDERS; RANDOM ALLOCATION; RECEPTORS, N-METHYL-D-ASPARTATE; SPEECH;

EID: 84879783367     PISSN: 10914269     EISSN: 15206394     Source Type: Journal    
DOI: 10.1002/da.22047     Document Type: Article

References (34)

1. Davis M, Ressler K, Rothbaum BO, Richardson R,. Effects of D-Cycloserine on extinction: translation from preclinical to clinical work. Biol Psychiatry 2006; 60 (4): 369-375.
2. Deveney CM, McHugh RK, Tolin DF, et al. Combining D-Cycloserine and exposure-based CBT for the anxiety disorders. Clin Neuropsychiatry 2009; 6 (2): 75-82.
3. Guastella AJ, Richardson R, Lovibond PF, et al. A randomized controlled trial of D-Cycloserine enhancement of exposure therapy for social anxiety disorder. Biol Psychiatry 2008; 63 (6): 544-549.
4. Norberg MM, Krystal JH, Tolin DF,. A meta-analysis of D-Cycloserine and the facilitation of fear extinction and exposure therapy. Biol Psychiatry 2008; 63 (12): 1118-1126.
5. Otto MW, Tolin DF, Simon NM, et al. Efficacy of D-Cycloserine for enhancing response to cognitive-behavior therapy for panic disorder. Biol Psychiatry 2010; 67 (4): 365-370.
6. Ressler KJ, Rothbaum BO, Tannenbaum L, et al. Cognitive enhancers as adjuncts to psychotherapy: use of D-Cycloserine in phobic individuals to facilitate extinction of fear. Arch Gen Psychiatry 2004; 61 (11): 1136-1144.
7. Hofmann SG, Meuret AE, Smits JAJ, et al. Augmentation of exposure therapy with D-Cycloserine for social anxiety disorder. Arch Gen Psychiatry 2006; 63 (3): 298-304.
8. Kola I, Landis J,. Can the pharmaceutical industry reduce attrition rates? Nature reviews. Drug Discov 2004; 3 (8): 711-715.
9. Paul SM, Mytelka DS, Dunwiddie CT, et al. How to improve R&D productivity: the pharmaceutical industry's grand challenge. Nature reviews. Drug Discov 2010; 9 (3): 203-214.
10. Wells A, Clark DM, Salkovskis P, et al. Social phobia: the role of in-situation safety behaviors in maintaining anxiety and negative beliefs. Behav Ther 1995; 26: 153-161.
11. Wells A, Papageorgiou C,. Social phobia: effects of external attention on anxiety, negative beliefs, and perspective taking. Behav Ther 1998; 29 (3): 357-370.
12. Rodebaugh TL, Heimberg RG, Schultz LT, Blackmore M,. The moderated effects of video feedback for social anxiety disorder. J Anxiety Disord 2010; 24 (7): 663-671.
13. Mystkowski JL, Craske MG, Echiverri AM,. Treatment context and return of fear in spider phobia. Behav Ther 2002; 33 (3): 399-416.
14. Mystkowski JL, Mineka S, Vernon LL, Zinbarg RE,. Changes in caffeine states enhance return of fear in spider phobia. J Consult Clin Psychol 2003; 71 (2): 243-250.
15. Guastella AJ, Dadds MR, Lovibond PF, et al. A randomized controlled trial of the effect of D-Cycloserine on exposure therapy for spider fear. J Psychiatr Res 2007; 41 (6): 466-471.
16. Kessler RC, Berglund P, Demler O, et al. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey replication. Arch Gen Psychiatry 2005; 62 (6): 593-602.
17. Ruscio AM, Brown TA, Chiu WT, et al. Social fears and social phobia in the USA: results from the National Comorbidity Survey replication. Psychol Med 2008; 38: 15-28.
18. Stein MB, Walker JR, Forde DR,. Public speaking fears in a community sample: prevalence, impact on functioning, and diagnostic classification. Arch Gen Psychiatry 1996; 53 (2): 169-174.
19. Chasson GS, Buhlmann U, Tolin DF, et al. Need for speed: evaluating slopes of OCD recovery in behavior therapy enhanced with D-Cycloserine. Behav Res Ther 2010; 48 (7): 675-679.
20. Clark DM, Ehlers A, McManus F, et al. Cognitive therapy vs fluoxetine in generalized social phobia: a randomized placebo controlled trial. J Consult Clin Psychol 2003; 71: 1058-1067.
21. Heimberg RG, Liebowitz MR, Hope DA, et al. Cognitive-behavioral group therapy vs phenelzine therapy for social phobia: 12-week outcome. Arch Gen Psychiatry 1998; 55: 1133-1141.
22. Sheehan DV, Lecrubier Y, Sheehan KH, et al. The Mini-International Neuropsychiatric Interview (M.I.N.I): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 1998; 59 (Suppl 20): 22-33.
23. Mennin DS, Fresco DM, Heimberg RG, et al. Screening for social anxiety disorder in the clinical setting: using the Liebowitz Social Anxiety Scale. J Anxiety Disord 2002; 16 (6): 661-673.
24. Liebowitz MR,. Social phobia. Mod Probl Pharmacopsychiatry 1987; 22: 141-173.
25. Wolpe J,. Subjective anxiety scale. In:, Hersen M, Bellack AS, editors. Dictionary of Behavioral Assessment Techniques. New York: Pergamon; 1988: 455-457.
26. Hope DA, Heimberg RG, Juster HR, Turk CL,. Managing Social Anxiety: A Cognitive-Behavioral Therapy Approach. New York: Oxford University Press. 2006.
27. Mattick RP, Clarke JC,. Development and validation of measures of social phobia scrutiny fear and social interaction anxiety. Behav Res Ther 1998; 36: 455-470.
28. Miller GA, Chapman JP,. Misunderstanding analysis of covariance. J Abnorm Psychol 2001; 110: 40-48.
29. Graham BM, Langton JM, Richardson R,. Pharmacological enhancement of fear reduction: preclinical models. Br J Pharmacol 2011; 164 (4): 1230-1247.
30. Millan MJ, Agid Y, Brune M, et al. Cognitive dysfunction in psychiatric disorders: characteristics, causes and the quest for improved therapy. Nature reviews. Drug Discov 2012; 11 (2): 141-68.
31. Werner-Seidler A, Richardson R,. Effects of D-Cycloserine on extinction: consequences of prior exposure to imipramine. Biol Psychiatry 2007; 62 (10): 1195-1197.
32. Langton JM, Richardson R,. The effect of D-Cycloserine on immediate vs. delayed extinction of learned fear. Learn Mem 2010; 17 (11): 547-551.
33. Kalisch R, Holt B, Petrovic P, et al. The NMDA agonist D-Cycloserine facilitates fear memory consolidation in humans. Cereb Cortex 2009; 19 (1): 187-196.
34. Leon AC,. Two clinical trial designs to examine personalized treatments for psychiatric disorders. J Clin Psychiatry 2011; 72 (5): 593-7.